William Maier PhD, PgD, MPH

William Maier


Dr. William Maier, PhD, Mapi’s Chief Scientific Officer, has more than 20 years of drug development and commercialization experience, and he provides invaluable insight to sponsors.

His promotion of a new pharmacoepidemiology, risk management, and research methodology—and his application of innovative technology to improve efficiency and accuracy of post-marketing surveillance studies—has proven invaluable to rare disease researchers. 

Dr. Maier has been involved in drug development and regulatory negotiations for products indicated for the following rare / orphan indications: 

  • Corneal cystine crystal deposits 
  • Stem Cell Mobilisation in Healthy Donors 
  • Severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS) following haematopoietic stem-cell transplantation (HSCT) therapy 
  • Primary Immunodeficiency (PI) in adults. This included, but was not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott- Aldrich syndrome, and severe combined immunodeficiencies 
  • Cystic Fibrosis 
  • Genetic variants of amyloid plaque development in Alzheimer’s Disease 
  • Primary and secondary progressive Multiple Sclerosis 
  • Crohn’s Disease and Ulcerative Colitis 
  • Autosomal dominant polycystic kidney disease (ADPKD) 
  • Levoleucovorin for Use In Combination Chemotherapy With 5-Fluorouracil In The Palliative Treatment Of Patients With Advanced Metastatic Colorectal Cancer: given orphan drug definition by FDA 

He has also conducted research projects for the follow rare disease areas:  

  • Cushing’s syndrome 
  • Duchenne’s muscular dystrophy (DMD) 
  • Progressive Multifocal Leukoencephalopathy (PML) 
  • Niemann-Pick type C disease 
  • Metastatic colorectal cancer (mCRC) 
  • Malignant glioma 
  • Short bowel syndrome (SBS) 
  • Dupuytren’s contracture 
  • Achondroplasia 
  • Multiple myeloma 
  • Transfusion-dependent anaemia due to myelodysplastic syndrome 
  • Insulin-like growth factor-1 Deficiency (IGF-1) 
  • Idiopathic pulmonary fibrosis (IPF) 
  • Hepatic encephalopathy chronic hypoparathyroidism 
  • N-Acetyl glutamate synthase deficiency 
  • Vitreomacular traction lipoprotein lipase-deficiency (LPL)

Employment History / Recent Positions

Consulting Companies

Actelion, ALK, Amgen, Aptalis, Astellas, AstraZeneca, BAT, Bayer, Biocodex, Celgene, Cortendo, Crucell, Elan Pharmaceutical, Ferring, Ipsen, J&J, Galderma, Gentium, GSK-Bio, Hospira, Ipsen, Laboratorie SMB, Lundbeck, Medtronic, Millenium, Mundipharma, Norgine, Pfizer, Retrophin, Roche, Sanofi, Sanofi-MSD, Santen, Schering- Plough, Shire, Sigma-Tau, Stallergene, Takeda, Targanta 

Member of European Medicines Agency sponsored Network of Centres of Excellence of Pharmacoepidemiology and Pharmacovigilance (ENCEPP) 


GSK, Elan Pharmaceutical, Pfizer (previously Parke-Davis), Parexel, PPD, Immunetech Pharmaceuticals 


University of Nottingham
Organisational Development / Tavistock Institute : PhD 

University of North Carolina at Chapel Hill
Epidemiology : PhD 

San Diego State University-California State University
Epidemiology, Biostatistics : MPH 

University of California, San Diego
Biochemistry and Cell Biology : Bachelor’s degree 

  • Post transplant lymphoprolifererative syndrome following liver transplant 
  • Post transplant lymphoprolifererative syndrome following renal transplant 
  • Post transplant lymphoprolifererative syndrome following heart transplant 
  • Behcets syndrome 
  • Chronic autoimmune thyroiditis and Graves’ Disease 
  • Auto immune haemolytic anaemia 
  • Antiphospholipid syndrome - primary 
  • Immune Thrombocytopenia Purpura 
  • Henoch-Schonlein Purpura 
  • Autoimmune neutropenia 
  • Myasthenia gravis 
  • Lambert Eaton myasthenic syndrome (LEMS) 
  • Stiff-person syndrome - amphiphysin-IgG 
  • Guillain-Barre syndrome (GBS) 
  • Optic neuritis 
  • Acute disseminated encephalomyelitis 
  • Chronic inflammatory demyelinating polyneuropathy 
  • Distal acquired demyelinating symmetric polyneuropathy (DADS) 
  • Coeliac disease 
  • Glomerulonephritis – IgA 
  • Pemphigus vulgaris 
  • Chronic idiopathic urticaria 
  • Vitiligo 
  • Systemic sclerosis / scleroderma, CREST syndrome 
  • Primary Sjogren’s disease / YeahSicca syndrome 
  • Dermatomyositis (DM) 
  • Reiter’s Arthritis 
  • Wegener’s granulomatosis 
  • Microscopic polyangitis (MPA) 
  • Polyarteritis nodosa primary systemic vasculitides 
  • Goodpasture’s syndrome (GPS) 
  • Thrombotic thrombocytopenic purpura (TTP) 
  • Juvenile rheumatoid arthritis 
  • Juvenile onset chronic polyarthritis / Still’s disease 
  • Lymphadenopathy Castleman disease (CD) 
  • Acute humoral (NONCELLUAR) graft rejection (AHR)